

Paul Schulwitz

119391

U.S. DEPARTMENT OF COMMERCE  
Patent and Trademark Office

# SEARCH REQUEST FORM

Requestor's Name: Reluma look <sup>313</sup> Serial Number: 09/047802

Date: 4/12/04 Phone: 15101 Art Unit: 1610

Chem 4070

11E1

## Search Topic:

inv. Robert Shov

Please write a detailed statement of search topic. Describe specifically as possible the subject matter to be searched. Define any terms that may have a special meaning. Give examples or relevant citations, authors, keywords, etc., if known. For sequences, please attach a copy of the sequence. You may include a copy of the broadest and/or most relevant claim(s).

Please search the attached compound of formula I  
(cl II) to treat cancer/neoplasm/  
metastasis & the methods of claims 19, 20,  
21. Search in caplus, medline & any other  
appropriate DBs

Thanks

Reluma

Rush Court Approved

TK Roy

SPE, 1615

## STAFF USE ONLY

Date completed: \_\_\_\_\_

Searcher: \_\_\_\_\_

Terminal time: \_\_\_\_\_

Elapsed time: \_\_\_\_\_

CPU time: \_\_\_\_\_

Total time: \_\_\_\_\_

Number of Searches: \_\_\_\_\_

Number of Databases: \_\_\_\_\_

### Search Site

\_\_\_\_\_ STIC

\_\_\_\_\_ CM-1

\_\_\_\_\_ Pre-S

### Type of Search

\_\_\_\_\_ N.A. Sequence

\_\_\_\_\_ A.A. Sequence

1 Structure

\_\_\_\_\_ Bibliographic

### Vendors

\_\_\_\_\_ IG

402.76 STN

\_\_\_\_\_ Dialog

\_\_\_\_\_ APS

\_\_\_\_\_ Geninfo

\_\_\_\_\_ SDC


\_\_\_\_\_ DARC/Questel

\_\_\_\_\_ Other

=&gt; d que 113

L1

STR



## NODE ATTRIBUTES:

CONNECT IS X3 RC AT 16

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

## GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED


NUMBER OF NODES IS 18

## STEREO ATTRIBUTES: NONE

L3 87 SEA FILE=REGISTRY SSS FUL L1

L5

STR



## NODE ATTRIBUTES:

CONNECT IS E2 RC AT 5

CONNECT IS X3 RC AT 16

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

## GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED


NUMBER OF NODES IS 18

## STEREO ATTRIBUTES: NONE

L6 2 SEA FILE=REGISTRY SUB=L3 SSS FUL L5

L7

STR



VAR G2=O/N/S/C

VAR G3=24/25

NODE ATTRIBUTES:

CONNECT IS X3 RC AT 16

CONNECT IS E2 RC AT 20

CONNECT IS E1 RC AT 24

CONNECT IS E1 RC AT 25

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 25

STEREO ATTRIBUTES: NONE

L8 36 SEA FILE=REGISTRY SUB=L3 SSS FUL L7


L12 12 SEA FILE=MEDLINE ABB=ON PLU=ON (L6 OR L8)

L13 0 SEA FILE=MEDLINE ABB=ON PLU=ON L12 AND (?CANCER? OR ?NEOPLAS?  
OR ?CARCIN? OR ?TUMOR? OR ?TUMOUR? OR ?METAST?)

=&gt; d que l11

L1

STR



## NODE ATTRIBUTES:

CONNECT IS X3 RC AT 16

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

## GRAPH ATTRIBUTES:


RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 18

## STEREO ATTRIBUTES: NONE

L3 87 SEA FILE=REGISTRY SSS FUL L1

L5 STR



## NODE ATTRIBUTES:

CONNECT IS E2 RC AT 5

CONNECT IS X3 RC AT 16

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

## GRAPH ATTRIBUTES:


RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 18

## STEREO ATTRIBUTES: NONE

L6 2 SEA FILE=REGISTRY SUB=L3 SSS FUL L5

L7 STR



VAR G2=O/N/S/C

VAR G3=24/25

NODE ATTRIBUTES:

CONNECT IS X3 RC AT 16

CONNECT IS E2 RC AT 20

CONNECT IS E1 RC AT 24

CONNECT IS E1 RC AT 25

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 25

STEREO ATTRIBUTES: NONE

L8 36 SEA FILE=REGISTRY SUB=L3 SSS FUL L7

L10 23 SEA FILE=HCAPLUS ABB=ON PLU=ON (L6 OR L8) (L) (BAC OR DMA OR  
PAC OR PKT OR THU)/RL

L11 2 SEA FILE=HCAPLUS ABB=ON PLU=ON L10 AND (?CANCER? OR ?NEOPLAS?  
OR ?CARCIN? OR ?TUMOR? OR ?TUMOUR? OR ?METAST?)

=> d l11 ibib ab hitind hitstr 1-2)

L11 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2003:678597 HCAPLUS

DOCUMENT NUMBER: 139:219309

TITLE: Prostacyclin derivative-containing compositions and  
methods of using the same for the treatment of

**cancer**

INVENTOR(S): Shorr, Robert; Rothblatt, Martine

PATENT ASSIGNEE(S): United Therapeutics Corporation, USA

SOURCE: PCT Int. Appl., 65 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.

KIND DATE

APPLICATION NO. DATE

-----  
 WO 2003070163 A2 20030828 WO 2003-US1483 20030116  
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,  
 CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,  
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,  
 PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,  
 UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU,  
 TJ, TM  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,  
 CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC,  
 NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,  
 ML, MR, NE, SN, TD, TG

US 2003166728 A1 20030904 US 2002-47802 20020116

PRIORITY APPLN. INFO.: US 2002-47802 A 20020116

OTHER SOURCE(S): MARPAT 139:219309

AB The present invention is directed to a pharmaceutical compn. contg. a  
**cancer**-treating effective amt. of a class of prostacyclin derivs.,  
 and a pharmaceutically acceptable carrier, and to kits and methods of  
 employing the same for the treatment of **cancer**. For example,  
 the prostacyclin deriv. inhibited protein degrdn. and promoted apoptosis  
 of human amelanotic melanoma cells.

IC ICM A61K

CC 63-6 (Pharmaceuticals)

Section cross-reference(s): 1, 25

ST prostacyclin protein degrdn inhibitor **cancer**

IT Prostaglandins

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)

(I; compns. contg. prostacyclin deriv. for **cancer** treatment)

IT Melanoma

(amelanotic; compns. contg. prostacyclin deriv. for **cancer**  
 treatment)

IT **Antitumor** agents

Human

**Neoplasm**

(compns. contg. prostacyclin deriv. for **cancer** treatment)

IT Collagens, biological studies

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (degrdn., inhibition of; compns. contg. prostacyclin deriv. for  
**cancer** treatment)

IT Drug delivery systems

(inhalants; compns. contg. prostacyclin deriv. for **cancer**  
 treatment)

IT Drug delivery systems

(injections, i.v.; compns. contg. prostacyclin deriv. for  
**cancer** treatment)

IT Drug delivery systems

(injections, s.c.; compns. contg. prostacyclin deriv. for  
**cancer** treatment)

IT Drug delivery systems

(kits; compns. contg. prostacyclin deriv. for **cancer**  
 treatment)

IT **Neoplasm**

(**metastasis**, inhibition of; compns. contg. prostacyclin  
 deriv. for **cancer** treatment)

IT Drug delivery systems  
(oral; compns. contg. prostacyclin deriv. for **cancer** treatment)

IT Drug delivery systems  
(parenterals; compns. contg. prostacyclin deriv. for **cancer** treatment)

IT Apoptosis  
(promotion of; compns. contg. prostacyclin deriv. for **cancer** treatment)

IT Extracellular matrix  
(protein degrdn. in, inhibition of; compns. contg. prostacyclin deriv. for **cancer** treatment)

IT **343247-13-2P**  
RL: **PAC (Pharmacological activity)**; SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)  
(compns. contg. prostacyclin deriv. for **cancer** treatment)

IT 823-96-1 6971-51-3, 3-Methoxybenzyl alcohol 22348-32-9 223734-62-1  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(compns. contg. prostacyclin deriv. for **cancer** treatment)


IT 94956-98-6P 101692-01-7P 101692-02-8P 101692-03-9P 101758-87-6P  
136911-16-5P 153974-48-2P 223734-55-2P 223734-56-3P 223734-57-4P  
223734-58-5P 223734-59-6P 223734-60-9P 223734-61-0P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(compns. contg. prostacyclin deriv. for **cancer** treatment)

IT **343247-13-2P**  
RL: **PAC (Pharmacological activity)**; SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)  
(compns. contg. prostacyclin deriv. for **cancer** treatment)

RN 343247-13-2 HCAPLUS

CN Acetic acid, [[(1R,2R,3aS,9aS)-2,3,3a,4,9,9a-hexahydro-2-hydroxy-1-[(3R)-3-hydroxyoctyl]-1H-benz[f]inden-5-yl]oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L11 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2004 ACS on STN  
ACCESSION NUMBER: 2002:720700 HCAPLUS  
DOCUMENT NUMBER: 138:19862  
TITLE: The Prostacyclin Analogue Treprostinil Blocks  
NF.kappa.B Nuclear Translocation in Human Alveolar

**Macrophages**

**AUTHOR(S):** Raychaudhuri, Baisakhi; Malur, Anagha; Bonfield, Tracey L.; Abraham, Susamma; Schilz, Robert J.; Farver, Carol F.; Kavuru, Mani S.; Arroliga, Alejandro C.; Thomassen, Mary Jane

**CORPORATE SOURCE:** Department of Pulmonary and Critical Care Medicine, The Cleveland Clinic Foundation, Cleveland, OH, 44195-5038, USA

**SOURCE:** Journal of Biological Chemistry (2002), 277(36), 33344-33348 *W2602*

**PUBLISHER:** CODEN: JBCHA3; ISSN: 0021-9258  
American Society for Biochemistry and Molecular Biology

**DOCUMENT TYPE:** Journal

**LANGUAGE:** English

**AB** Primary pulmonary hypertension (PPH) is characterized by increased pulmonary arterial pressure and vascular resistance. We and others have obsd. that inflammatory cytokines and infiltrates are present in the lung tissue, but the significance is uncertain. Treprostinil (TRE), a prostacyclin analog with extended half-life and chem. stability, has shown promise in the treatment of PPH. We hypothesize that TRE might exert beneficial effects in PPH by antagonizing inflammatory cytokine prodn. in the lung. Here we show that TRE dose-dependently inhibits inflammatory cytokine (**tumor** necrosis factor-.alpha., interleukin-1.beta., interleukin-6, and granulocyte macrophage colony-stimulating factor) secretion and gene expression by human alveolar macrophages. TRE blocks NF.kappa.B activation, but I.kappa.B-.alpha. phosphorylation and degrdn. are unaffected. Moreover, TRE does not affect the formation of the NF.kappa.B.cntdot.DNA complex but blocks nuclear translocation of p65. These results are the first to illustrate the anti-cytokine actions of TRE in down-regulating NF.kappa.B, not through its inhibitory component or by direct binding but by blocking nuclear translocation. These data indicate that inflammatory mechanisms may be important in the pathogenesis of PPH and cytokine antagonism by blocking NF.kappa.B may contribute to the efficacy of TRE therapy in PPH.

**CC** 2-9 (Mammalian Hormones)

**IT** Interleukin 1.beta.  
Interleukin 6  
**Tumor** necrosis factors


**RL:** BSU (Biological study, unclassified); BIOL (Biological study) (prostacyclin analog treprostinil blocks inflammatory cytokine secretion and NF.kappa.B nuclear translocation in human alveolar macrophages in relation to it use in primary pulmonary hypertension treatment)

**IT** **81846-19-7, Treprostinil**  
**RL:** **DMA (Drug mechanism of action);** BIOL (Biological study) (prostacyclin analog treprostinil blocks inflammatory cytokine secretion and NF.kappa.B nuclear translocation in human alveolar macrophages in relation to it use in primary pulmonary hypertension treatment)

**IT** **81846-19-7, Treprostinil**  
**RL:** **DMA (Drug mechanism of action);** BIOL (Biological study) (prostacyclin analog treprostinil blocks inflammatory cytokine secretion and NF.kappa.B nuclear translocation in human alveolar macrophages in relation to it use in primary pulmonary hypertension treatment)

**RN** 81846-19-7 HCAPLUS

Absolute stereochemistry.




THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=&gt; d que

L1

STR



## NODE ATTRIBUTES:

CONNECT IS X3 RC AT 16

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

## GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED


NUMBER OF NODES IS 18

## STEREO ATTRIBUTES: NONE

L3 87 SEA FILE=REGISTRY SSS FUL L1

L7

STR



N @24 O @25

VAR G2=O/N/S/C

VAR G3=24/25

## NODE ATTRIBUTES:

CONNECT IS X3 RC AT 16

CONNECT IS E2 RC AT 20

CONNECT IS E1 RC AT 24

CONNECT IS E1 RC AT 25

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

## GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 25

STEREO ATTRIBUTES: NONE

L8 36 SEA FILE=REGISTRY SUB=L3 SSS FUL L7  
L17 85 SEA L8  
L18 6 SEA L17 AND (CANCER OR ANTICANC? OR NEOPLAS? OR ANTINEOPLAS?  
OR TUMOR? OR ANTITUM? OR METAST? OR CARCIN?)

=&gt; dup rem l18

PROCESSING COMPLETED FOR L18

L19 6 DUP REM L18 (0 DUPLICATES REMOVED)  
ANSWERS '1-2' FROM FILE BIOSIS  
ANSWERS '3-6' FROM FILE USPATFULL

(=&gt; d l19 bib ab 1-6)

L19 ANSWER 1 OF 6 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN  
AN 2003:417438 BIOSIS  
DN PREV200300417438  
TI 27th Meeting of the Oesterreichische Gesellschaft fuer Lungenerkrankungen und Tuberkulose, Alpbach, Tyrol, Austria, May, 29-June, 1, 2003.  
AU Oesterreichische Gesellschaft fuer Lungenerkrankungen und Tuberkulose  
SO Wiener Klinische Wochenschrift, (30 Mai 2003) Vol. 115, No. 10, pp. A IV-A XIII. print.  
Meeting Info.: 27th Meeting of the Oesterreichische Gesellschaft fuer Lungenerkrankungen und Tuberkulose. Alpbach, Tyrol, Austria. May 29-June 01, 2003. Oesterreichische Gesellschaft fuer Lungenerkrankungen und Tuberkulose.  
CODEN: WKWOAO. ISSN: 0043-5325.  
DT Conference; (Meeting)  
Conference; (Meeting Summary)  
LA English  
ED Entered STN: 10 Sep 2003  
Last Updated on STN: 10 Sep 2003  
AB This meeting contains abstracts of 33 papers, written in German and English, on a variety of topics in lung diseases in the human patient, including asthma bronchiale, sleep apnea syndrome, bronchial **carcinoma**, pancreatic **tumor**, tuberculosis, lung **cancer**, respiratory failure, actinomycosis, HIV, pulmonary arterial hypertension, ventilation, autofluorescence bronchoscopy, bronchoscopy, endoscopy simulator, smoking cessation therapy, nebulizer therapy, bronchoalveolar lavage, mycophenolate mofetil, treprostinil, high-altitude medicine, and genetics.

L19 ANSWER 2 OF 6 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN  
AN 2002:535469 BIOSIS  
DN PREV200200535469  
TI The prostacyclin analogue treprostinil blocks NFkappaB nuclear translocation in human alveolar macrophages.  
AU Raychaudhuri, Baisakhi; Malur, Anagha; Bonfield, Tracey L.; Abraham, Susamma; Schilz, Robert J.; Farver, Carol F.; Kavuru, Mani S.; Arroliga, Alejandro C.; Thomassen, Mary Jane [Reprint author]  
CS Dept. of Pulmonary and Critical Care Medicine, Cleveland Clinic Foundation, 9500 Euclid Ave., Desk A90, Cleveland, OH, 44195-5038, USA thomasm@ccf.org  
SO Journal of Biological Chemistry, (September 6, 2002) Vol. 277, No. 36, pp. 33344-33348. print.  
CODEN: JBCHA3. ISSN: 0021-9258.

DT Article  
 LA English  
 ED Entered STN: 16 Oct 2002  
 Last Updated on STN: 16 Oct 2002  
 AB Primary pulmonary hypertension (PPH) is characterized by increased pulmonary arterial pressure and vascular resistance. We and others have observed that inflammatory cytokines and infiltrates are present in the lung tissue, but the significance is uncertain. Treprostinil (TRE), a prostacyclin analogue with extended half-life and chemical stability, has shown promise in the treatment of PPH. We hypothesize that TRE might exert beneficial effects in PPH by antagonizing inflammatory cytokine production in the lung. Here we show that TRE dose-dependently inhibits inflammatory cytokine (**tumor** necrosis factor-alpha, interleukin-1beta, interleukin-6, and granulocyte macrophage colony-stimulating factor) secretion and gene expression by human alveolar macrophages. TRE blocks NFkappaB activation, but IkappaB-alpha phosphorylation and degradation are unaffected. Moreover, TRE does not affect the formation of the NFkappaBcntdotDNA complex but blocks nuclear translocation of p65. These results are the first to illustrate the anti-cytokine actions of TRE in down-regulating NFkappaB, not through its inhibitory component or by direct binding but by blocking nuclear translocation. These data indicate that inflammatory mechanisms may be important in the pathogenesis of PPH and cytokine antagonism by blocking NFkappaB may contribute to the efficacy of TRE therapy in PPH.

L19 ANSWER 3 OF 6 USPATFULL on STN  
 AN 2003:307038 USPATFULL  
 TI Method of using prostacyclin to treat respiratory syncytial virus infections  
 IN Peebles, Ray Stokes, JR., Nashville, TN, UNITED STATES  
 Hashimoto, Koichi, Fukushima, JAPAN  
 Graham, Barney S., Rockville, MD, UNITED STATES  
 PI US 2003216474 A1 20031120  
 AI US 2003-389295 A1 20030314 (10)  
 PRAI US 2002-364395P 20020315 (60)  
 DT Utility  
 FS APPLICATION  
 LREP WADDEY & PATTERSON, 414 UNION STREET, SUITE 2020, BANK OF AMERICA PLAZA, NASHVILLE, TN, 37219  
 CLMN Number of Claims: 20  
 ECL Exemplary Claim: 1  
 DRWN 9 Drawing Page(s)  
 LN.CNT 1178

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention discloses methods and a kit for treating a respiratory syncytial virus infection. The method comprises providing an infection modulator, and administering a therapeutically effective amount of the infection modulator, wherein the respiratory syncytial virus infection is suppressed or precluded. The kit for suppressing a respiratory syncytial virus infection comprises an infection modulator, an applicator, and a set of instructions.

L19 ANSWER 4 OF 6 USPATFULL on STN  
 AN 2003:238570 USPATFULL  
 TI Prostacyclin derivative containing compositions and methods of using the same for the treatment of **cancer**  
 IN Shorr, Robert, Edison, NJ, UNITED STATES

Rothblatt, Martine, Silver Spring, MD, UNITED STATES  
PI US 2003166728 A1 20030904  
AI US 2002-47802 A1 20020116 (10)  
DT Utility  
FS APPLICATION  
LREP Allen R. Kipnes, WATOV & KIPNES, P.C., P.O. BOX 247, PRINCETON JUNCTION,  
NJ, 08550  
CLMN Number of Claims: 28  
ECL Exemplary Claim: 1  
DRWN 3 Drawing Page(s)  
LN.CNT 1196

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to a pharmaceutical composition containing a **cancer**-treating effective amount of a class of prostacyclin derivatives, and a pharmaceutically acceptable carrier, and to kits and methods of employing the same for the treatment of **cancer**.

L19 ANSWER 5 OF 6 USPATFULL on STN  
AN 2003:159865 USPATFULL  
TI Inhibitors of endothelin-1 synthesis  
IN Corder, Roger, Harrow, UNITED KINGDOM  
Smith, Adrian P.L., London, UNITED KINGDOM  
Higenbottam, Timothy W., Sheffield, UNITED KINGDOM  
Rothblatt, Martine, Silver Spring, MD, UNITED STATES  
Vane, Sir John, London, UNITED KINGDOM  
Lees, Delphine Dominique Marthe, London, UNITED KINGDOM  
PA United Therapeutics Corporation (non-U.S. corporation)  
PI US 2003109480 A1 20030612  
AI US 2002-295942 A1 20021118 (10)  
RLI Continuation of Ser. No. US 2000-527240, filed on 17 Mar 2000, ABANDONED  
PRAI US 1999-125000P 19990318 (60)  
DT Utility  
FS APPLICATION  
LREP FOLEY AND LARDNER, SUITE 500, 3000 K STREET NW, WASHINGTON, DC, 20007  
CLMN Number of Claims: 54  
ECL Exemplary Claim: 1  
DRWN 19 Drawing Page(s)  
LN.CNT 1357

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Sequences in human preproendothelin-1 mRNA are described against which antisense oligonucleotides can be used to inhibit the synthesis of endothelin-1. This inhibition of endothelin-1 synthesis may be used to treat diseases where excess production of endothelin-1 is an underlying cause of the symptoms.

L19 ANSWER 6 OF 6 USPATFULL on STN  
AN 2003:158899 USPATFULL  
TI Modified prostaglandin compounds and analogs thereof, compositions containing the same useful for the treatment of **cancer**  
IN Shorr, Robert, Edison, NJ, UNITED STATES  
Rothblatt, Martine, Silver Spring, MD, UNITED STATES  
Bentley, Michael, Huntsville, AL, UNITED STATES  
Zhao, Xuan, Huntsville, AL, UNITED STATES  
PI US 2003108512 A1 20030612  
AI US 2001-6197 A1 20011210 (10) *abandoned*  
DT Utility

FS APPLICATION

LREP Allen R. Kipnes, WATOV & KIPNES, P.C., P.O. BOX 247, PRINCETON JUNCTION,  
NJ, 08550

CLMN Number of Claims: 52

ECL Exemplary Claim: 1

DRWN 4 Drawing Page(s)

LN.CNT 1415


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention is directed to a pharmaceutical composition containing a  
**cancer**-treating effective amount of a prostaglandin compound and  
analogs thereof having a metabolic rate slowing group attached thereto,  
and a pharmaceutically acceptable carrier, and methods of employing the  
same for the treatment of **cancer**.

=&gt; d que 115

L1

STR



NODE ATTRIBUTES:

CONNECT IS X3 RC AT 16

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED


NUMBER OF NODES IS 18

STEREO ATTRIBUTES: NONE

L3 87 SEA FILE=REGISTRY SSS FUL L1

L5

STR



NODE ATTRIBUTES:

CONNECT IS E2 RC AT 5

CONNECT IS X3 RC AT 16

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED


NUMBER OF NODES IS 18

STEREO ATTRIBUTES: NONE

L6 2 SEA FILE=REGISTRY SUB=L3 SSS FUL L5

L7

STR



VAR G2=O/N/S/C

VAR G3=24/25

NODE ATTRIBUTES:

CONNECT IS X3 RC AT 16

CONNECT IS E2 RC AT 20

CONNECT IS E1 RC AT 24

CONNECT IS E1 RC AT 25

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 25

STEREO ATTRIBUTES: NONE

L8 36 SEA FILE=REGISTRY SUB=L3 SSS FUL L7

L14 108 SEA FILE=EMBASE ABB=ON PLU=ON L6 OR L8

L15 8 SEA FILE=EMBASE ABB=ON PLU=ON L14 AND (?CANCER? OR ?NEOPLAS?  
OR ?CARCIN? OR ?TUMOR? OR ?TUMOUR? OR ?METAST?)

=> d l15 ibib ab hitind 1-8

L15 ANSWER 1 OF 8 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED.  
on STN

ACCESSION NUMBER: 2003448000 EMBASE

TITLE: New drug approvals for 2002.

AUTHOR: Frantz S.; Smith A.

CORPORATE SOURCE: S. Frantz. s.frantz@nature.com

SOURCE: Nature Reviews Drug Discovery, (2003) 2/2 (95-96).

Refs: 1

ISSN: 1474-1776 CODEN: NRDDAG

COUNTRY: United Kingdom

DOCUMENT TYPE: Journal; Note

FILE SEGMENT: 006 Internal Medicine

016 Cancer

030 Pharmacology

037 Drug Literature Index

LANGUAGE: English

CT Medical Descriptors:

\*drug approval  
drug marketing  
drug mechanism  
food and drug administration  
hypertension: DT, drug therapy  
**breast metastasis: DT, drug therapy**  
pulmonary hypertension: DT, drug therapy  
aspergillosis: DT, drug therapy  
heart disease: DT, drug therapy  
narcolepsy: DT, drug therapy  
cataplexy: DT, drug therapy  
irritable colon: DT, drug therapy  
**colorectal cancer: DT, drug therapy**  
hepatitis B: DT, drug therapy  
hypercholesterolemia: DT, drug therapy  
schizophrenia: DT, drug therapy  
diarrhea: DT, drug therapy  
cryptosporidiosis: DT, drug therapy  
giardiasis: DT, drug therapy  
osteoporosis: DT, drug therapy  
keratoconjunctivitis sicca: DT, drug therapy  
migraine: DT, drug therapy  
bacterial infection: DT, drug therapy  
Alzheimer disease: DT, drug therapy  
influenza: DT, drug therapy  
erectile dysfunction: DT, drug therapy  
osteoarthritis: DT, drug therapy  
rheumatoid arthritis: DT, drug therapy  
human  
note  
priority journal  
Drug Descriptors:  
\*new drug: DT, drug therapy  
\*new drug: PD, pharmacology  
olmesartan: DT, drug therapy  
olmesartan: PD, pharmacology  
fulvestrant: DT, drug therapy  
fulvestrant: PD, pharmacology  
uniprost: DT, drug therapy  
uniprost: PD, pharmacology  
voriconazole: DT, drug therapy  
voriconazole: PD, pharmacology  
dimyristoylphosphatidylcholine: DT, drug therapy  
dimyristoylphosphatidylcholine: PD, pharmacology  
oxybate sodium: DT, drug therapy  
oxybate sodium: PD, pharmacology  
tegaserod: DT, drug therapy  
tegaserod: PD, pharmacology  
oxaliplatin: CB, drug combination  
oxaliplatin: DT, drug therapy  
oxaliplatin: PD, pharmacology  
fluorouracil: CB, drug combination  
fluorouracil: DT, drug therapy  
folinic acid: CB, drug combination  
folinic acid: DT, drug therapy  
adefovir dipivoxil: DT, drug therapy  
adefovir dipivoxil: PD, pharmacology

eplerenone: DT, drug therapy  
 eplerenone: PD, pharmacology  
 ezetimibe: DT, drug therapy  
 ezetimibe: PD, pharmacology  
 hypocholesterolemic agent: DT, drug therapy  
 hypocholesterolemic agent: PD, pharmacology  
 aripiprazole: DT, drug therapy  
 aripiprazole: PD, pharmacology  
 nitazoxanide: DT, drug therapy  
 nitazoxanide: PD, pharmacology  
 parathyroid hormone[1-34]: DT, drug therapy  
 parathyroid hormone[1-34]: PD, pharmacology  
 cyclosporin A: DT, drug therapy  
 cyclosporin A: PD, pharmacology  
 eletriptan: DT, drug therapy  
 eletriptan: PD, pharmacology  
 ertapenem: DT, drug therapy  
 ertapenem: PD, pharmacology  
 telmisartan: CB, drug combination  
 telmisartan: DT, drug therapy  
 telmisartan: PD, pharmacology  
 hydrochlorothiazide: CB, drug combination  
 hydrochlorothiazide: DT, drug therapy  
 hydrochlorothiazide: PD, pharmacology  
 bosentan: DT, drug therapy  
 bosentan: PD, pharmacology  
 memantine: DT, drug therapy  
 memantine: PD, pharmacology  
 oseltamivir: DT, drug therapy  
 oseltamivir: PD, pharmacology  
 tadalafil: DT, drug therapy  
 tadalafil: PD, pharmacology  
 valdecoxib: DT, drug therapy  
 valdecoxib: PD, pharmacology  
 vardenafil: DT, drug therapy  
 vardenafil: PD, pharmacology  
 unindexed drug

hepsera

inspra

alinia

micardis plus

prior plus

ebixa

axura

levitra

RN (olmesartan) 144689-63-4; (fulvestrant) 129453-61-8; (uniprost)  
**81846-19-7**; (voriconazole) 137234-62-9;  
 (dimyristoylphosphatidylcholine) 13699-48-4, 18194-24-6; (oxybate sodium)  
 502-85-2; (tegaserod) 145158-71-0, 189188-57-6; (oxaliplatin) 61825-94-3;  
 (fluorouracil) 51-21-8; (folinic acid) 58-05-9, 68538-85-2; (adefovir  
 dipivoxil) 142340-99-6; (eplerenone) 107724-20-9; (ezetimibe) 163222-33-1;  
 (aripiprazole) 129722-12-9; (nitazoxanide) 55981-09-4; (parathyroid  
 hormone[1-34]) 12583-68-5, 52232-67-4; (cyclosporin A) 59865-13-3,  
 63798-73-2; (eletriptan) 143322-58-1, 177834-92-3; (ertapenem)  
 153773-82-1, 153832-38-3, 153832-46-3; (telmisartan) 144701-48-4;  
 (hydrochlorothiazide) 58-93-5; (bosentan) 147536-97-8, 157212-55-0;  
 (memantine) 19982-08-2, 41100-52-1; (oseltamivir) 196618-13-0,

204255-09-4, 204255-11-8; (tadalafil) 171596-29-5; (valdecocixib)  
 181695-72-7; (vardenafil) 224785-90-4, 224785-91-5, 224789-15-5  
 CN (1) Benicar; (2) Faslodex; (3) Remodulin; (4) Xyrem; (5) Zelnorm; (6)  
 Eloxatin; (7) Hepsera; (8) Inspira; (9) Zetia; (10) Zetia; (11) Abilify;  
 (12) Abilify; (13) Alinia; (15) Forteo; (16) Relpax; (17) Invanz; (18)  
 Micardis plus; (19) Pritor plus; (20) Tracleer; (21) Ebixa; (22) Axura;  
 (23) Tamiflu; (24) Cialis; (25) Bextra; (26) Bextra; (27) Levitra  
 CO (1) Sankyo; (2) Astra Zeneca; (3) United Therapeutics; (4) Orphan; (5)  
 Novartis; (6) Sanofi Synthelabo; (7) Gilead; (8) Searle; (9) Merck  
 (Singapore); (10) Schering Plough (Singapore); (11) Otsuka; (12) Bristol  
 Myers Squibb; (13) Romark; (14) Lilly; (17) Merck Sharp and Dohme; (18)  
 Boehringer Ingelheim; (19) Glaxo SmithKline; (20) Actelion; (21) Lundbeck;  
 (22) Merz; (23) Hoffmann La Roche; (24) Lilly ICOS; (25) Pharmacia; (26)  
 Pfizer; (27) Bayer; Allergan; Alliance

L15 ANSWER 2 OF 8 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED.  
 on STN

ACCESSION NUMBER: 2003396573 EMBASE  
 TITLE: [Pulmonary hypertension].  
 PULMONALE HYPERTONIE.  
 AUTHOR: Petkov V.; Doberer D.  
 CORPORATE SOURCE: Dr. V. Petkov, Univ. Klin. fur Innere Medizin IV, Klinische  
 Abteilung fur Pulmologie, Wahringer Gurtel 18-20, A-1090  
 Wien, Austria. Ventzislav.Petkov@univie.ac.at  
 SOURCE: Journal fur Hypertonie, (2003) 7/3 (7-14).  
 Refs: 13  
 ISSN: 1028-2327 CODEN: JHYPFE  
 COUNTRY: Austria  
 DOCUMENT TYPE: Journal; (Short Survey)  
 FILE SEGMENT: 006 Internal Medicine  
 015 Chest Diseases, Thoracic Surgery and Tuberculosis  
 018 Cardiovascular Diseases and Cardiovascular Surgery  
 037 Drug Literature Index  
 038 Adverse Reactions Titles  
 LANGUAGE: German  
 SUMMARY LANGUAGE: English; German

AB Pulmonary Hypertension (PH) is a haemodynamic diagnosis caused by several  
 underlying diseases. In the last years tremendous progress in  
 pathophysiology, diagnostics and therapy of PH was made. These new  
 insights led to the first international classification of pulmonary  
 hypertension (Evian 1998) and at the end of the nineties the first  
 controlled trials were launched. Although further subdivision of different  
 aetiologies of PH will preceed, therapeutic approaches still follow the  
 haemodynamic profiles of PH. In this article we will focus on the  
 precapillary forms of PH, including the prototype primary pulmonary  
 hypertension, which are characterized by similar therapeutic strategies.

CT Medical Descriptors:  
 \*pulmonary hypertension: DI, diagnosis  
 \*pulmonary hypertension: DT, drug therapy  
 \*pulmonary hypertension: EP, epidemiology  
 \*pulmonary hypertension: ET, etiology  
 \*pulmonary hypertension: SI, side effect  
 \*pulmonary hypertension: SU, surgery  
 world health organization  
 disease classification  
 symptomatology  
 hemodynamic parameters

lung capillary pressure  
lung artery pressure  
lung vascular resistance  
risk factor  
disease association  
drug use  
drug abuse  
cigarette smoking  
estrogen therapy  
algorithm  
diagnostic test  
two dimensional echocardiography  
lung ventilation perfusion ratio  
lung scintiscanning  
computer assisted tomography  
conservative treatment  
lung transplantation  
anticoagulant therapy  
lung embolism: CO, complication  
lung embolism: DT, drug therapy  
lung embolism: PC, prevention  
human

short survey

**Drug Descriptors:**

\*prostacyclin derivative: AD, drug administration  
\*prostacyclin derivative: DO, drug dose  
\*prostacyclin derivative: DT, drug therapy  
\*prostacyclin derivative: IH, inhalational drug administration  
\*prostacyclin derivative: IV, intravenous drug administration  
\*prostacyclin derivative: PO, oral drug administration  
\*prostacyclin derivative: SC, subcutaneous drug administration  
\*calcium channel blocking agent: AD, drug administration  
\*calcium channel blocking agent: DT, drug therapy  
\*calcium channel blocking agent: PO, oral drug administration  
\*endothelin receptor antagonist: AD, drug administration  
\*endothelin receptor antagonist: DT, drug therapy  
\*endothelin receptor antagonist: PO, oral drug administration  
\*phosphodiesterase inhibitor: AD, drug administration  
\*phosphodiesterase inhibitor: DT, drug therapy  
\*phosphodiesterase inhibitor: PO, oral drug administration  
\*vasodilator agent: AD, drug administration  
\*vasodilator agent: DT, drug therapy  
\*vasodilator agent: PO, oral drug administration  
methamphetamine: TO, drug toxicity  
cocaine: TO, drug toxicity  
tryptophan: AE, adverse drug reaction  
aminorex: AE, adverse drug reaction  
fenfluramine: AE, adverse drug reaction  
**antineoplastic agent: AE, adverse drug reaction**  
antidepressant agent: AE, adverse drug reaction  
oral contraceptive agent: AE, adverse drug reaction  
oral contraceptive agent: AD, drug administration  
oral contraceptive agent: PO, oral drug administration  
estrogen: AE, adverse drug reaction  
diltiazem: AD, drug administration  
diltiazem: DT, drug therapy  
diltiazem: PO, oral drug administration

nifedipine: AD, drug administration  
 nifedipine: DT, drug therapy  
 nifedipine: PO, oral drug administration  
 prostacyclin: AD, drug administration  
 prostacyclin: DT, drug therapy  
 prostacyclin: IV, intravenous drug administration  
 iloprost: AD, drug administration  
 iloprost: DT, drug therapy  
 iloprost: IH, inhalational drug administration  
 iloprost: IV, intravenous drug administration  
 uniprost: AD, drug administration  
 uniprost: DT, drug therapy  
 uniprost: SC, subcutaneous drug administration  
 beraprost: AD, drug administration  
 beraprost: DT, drug therapy  
 beraprost: PO, oral drug administration  
 bosentan: AD, drug administration  
 bosentan: DT, drug therapy  
 bosentan: PO, oral drug administration  
 sildenafil: AD, drug administration  
 sildenafil: DT, drug therapy  
 sildenafil: PO, oral drug administration  
 vasoactive intestinal polypeptide: DT, drug therapy  
 dihydralazine: AD, drug administration  
 dihydralazine: DT, drug therapy  
 dihydralazine: PO, oral drug administration  
 urapidil: AD, drug administration  
 urapidil: DT, drug therapy  
 urapidil: PO, oral drug administration  
 coumarin anticoagulant: AD, drug administration  
 coumarin anticoagulant: DT, drug therapy  
 coumarin anticoagulant: PO, oral drug administration  
 digitalis: AD, drug administration  
 digitalis: DT, drug therapy  
 digitalis: PO, oral drug administration  
 diuretic agent: AD, drug administration  
 diuretic agent: DT, drug therapy  
 diuretic agent: PO, oral drug administration  
 dipeptidyl carboxypeptidase inhibitor: DT, drug therapy  
 unindexed drug

RN (methamphetamine) 28297-73-6, 51-57-0, 537-46-2, 7632-10-2; (cocaine) 50-36-2, 53-21-4, 5937-29-1; (tryptophan) 6912-86-3, 73-22-3; (aminorex) 13425-22-4, 2207-50-3; (fenfluramine) 404-82-0, 458-24-2; (diltiazem) 33286-22-5, 42399-41-7; (nifedipine) 21829-25-4; (prostacyclin) 35121-78-9, 61849-14-7; (iloprost) 78919-13-8, 82889-99-4; (uniprost) **81846-19-7**; (beraprost) 88430-50-6, 88475-69-8; (bosentan) 147536-97-8, 157212-55-0; (sildenafil) 139755-83-2; (vasoactive intestinal polypeptide) 37221-79-7; (dihydralazine) 484-23-1; (urapidil) 34661-75-1; (digitalis) 8031-42-3, 8053-83-6  
 CN Flolan; Ilomedin; Viagra; Tracleer

L15 ANSWER 3 OF 8 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED.  
 on STN

ACCESSION NUMBER: 2003252137 EMBASE

TITLE: [Consensus recommendations of the working group on pulmonary arterial hypertension of the Austrian Society for Lung Diseases and Tuberculosis].

KONSENSUS-EMPFEHLUNGEN DER ARBEITSGRUPPE PULMONALARTERIELLE  
HYPERTENSION DER OSTERREICHISCHEN GESELLSCHAFT FUR  
LUNGENERKRANKUNGEN UND TUBERKULOSE.

AUTHOR: Ziesche R.  
CORPORATE SOURCE: Dr. R. Ziesche, Klinische Abteilung fur Pulmologie, Univ.  
Klin. fur Innere Medizin IV, Wahringer Gurtel 18-20, A-1090  
Wien, Austria. rolf.ziesche@akh-wien.ac.at  
SOURCE: Wiener Klinische Wochenschrift, (30 May 2003) 115/10  
(351-365).  
Refs: 54  
ISSN: 0043-5325 CODEN: WKWOAO  
COUNTRY: Austria  
DOCUMENT TYPE: Journal; Conference Article  
FILE SEGMENT: 015 Chest Diseases, Thoracic Surgery and Tuberculosis  
037 Drug Literature Index  
038 Adverse Reactions Titles  
LANGUAGE: German  
CT Medical Descriptors:  
\*pulmonary hypertension: DI, diagnosis  
\*pulmonary hypertension: DT, drug therapy  
\*pulmonary hypertension: SI, side effect  
\*pulmonary hypertension: SU, surgery  
Austria  
medical society  
lung disease  
lung tuberculosis  
disease classification  
risk factor  
treatment indication  
liver toxicity: SI, side effect  
human  
conference paper  
Drug Descriptors:  
antidepressant agent: AE, adverse drug reaction  
oral contraceptive agent: AE, adverse drug reaction  
**antineoplastic agent: AE, adverse drug reaction**  
cocaine  
amphetamine  
aminorex: AE, adverse drug reaction  
fenfluramine: AE, adverse drug reaction  
phentermine: AE, adverse drug reaction  
tryptophan: AE, adverse drug reaction  
diltiazem: DT, drug therapy  
diltiazem: PO, oral drug administration  
nifedipine: DT, drug therapy  
nifedipine: PO, oral drug administration  
prostacyclin: DT, drug therapy  
prostacyclin: IV, intravenous drug administration  
iloprost: DT, drug therapy  
iloprost: IH, inhalational drug administration  
iloprost: IV, intravenous drug administration  
uniprost: DT, drug therapy  
uniprost: SC, subcutaneous drug administration  
beraprost: DT, drug therapy  
beraprost: PO, oral drug administration  
bosentan: AE, adverse drug reaction  
bosentan: DT, drug therapy

bosentan: PO, oral drug administration  
sildenafil: DT, drug therapy  
sildenafil: PO, oral drug administration  
vasoactive intestinal polypeptide: DT, drug therapy  
vasoactive intestinal polypeptide: IH, inhalational drug administration  
dihydralazine: DT, drug therapy  
dihydralazine: PO, oral drug administration  
urapidil: DT, drug therapy  
urapidil: PO, oral drug administration  
RN (cocaine) 50-36-2, 53-21-4, 5937-29-1; (amphetamine) 1200-47-1, 139-10-6,  
156-34-3, 2706-50-5, 300-62-9, 51-62-7, 60-13-9, 60-15-1; (aminorex)  
13425-22-4, 2207-50-3; (fenfluramine) 404-82-0, 458-24-2; (phentermine)  
1197-21-3, 122-09-8; (tryptophan) 6912-86-3, 73-22-3; (diltiazem)  
33286-22-5, 42399-41-7; (nifedipine) 21829-25-4; (prostacyclin)  
35121-78-9, 61849-14-7; (iloprost) 78919-13-8, 82889-99-4; (uniprost)  
**81846-19-7**; (beraprost) 88430-50-6, 88475-69-8; (bosentan)  
147536-97-8, 157212-55-0; (sildenafil) 139755-83-2; (vasoactive intestinal  
polypeptide) 37221-79-7; (dihydralazine) 484-23-1; (urapidil) 34661-75-1  
CN Remodulin; Flolan; Tracleer

L15 ANSWER 4 OF 8 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED.  
on STN

ACCESSION NUMBER: 2003250118 EMBASE  
TITLE: Recap of FDA product approvals - 2002.  
SOURCE: American Journal of Health-System Pharmacy, (15 Feb 2003)  
60/4 (310+312).  
ISSN: 1079-2082 CODEN: AHSPEK  
COUNTRY: United States  
DOCUMENT TYPE: Journal; Note  
FILE SEGMENT: 017 Public Health, Social Medicine and Epidemiology  
037 Drug Literature Index  
039 Pharmacy  
LANGUAGE: English

CT Medical Descriptors:  
\*drug approval  
food and drug administration  
rheumatoid arthritis  
attention deficit disorder  
irritable colon  
licensing  
drug indication  
\*malignant neoplastic disease  
human  
note  
priority journal  
Drug Descriptors:  
\*new drug  
vaccine  
orphan drug  
adalimumab  
ibritumomab tiuxetan  
fulvestrant  
oxaliplatin  
recombinant granulocyte colony stimulating factor  
rasburicase  
tegaserod  
diphtheria pertussis tetanus vaccine

oxybate sodium  
 nitazoxanide  
 uniprost  
 extraneal  
 strattera  
 elitek  
 daptacel  
 pediarix  
 alinia  
 orfadin  
 humira

RN (adalimumab) 331731-18-1; (ibritumomab tiuxetan) 206181-63-7;  
 (fulvestrant) 129453-61-8; (oxaliplatin) 61825-94-3; (recombinant  
 granulocyte colony stimulating factor) 121181-53-1; (rasburicase)  
 352311-12-7; (tegaserod) 145158-71-0, 189188-57-6; (oxybate sodium)  
 502-85-2; (nitazoxanide) 55981-09-4; (uniprost) **81846-19-7**  
 CN (1) Strattera; (2) Zevalin; (3) Faslodex; (4) Eloxatin; (5) Neulasta; (6)  
 Elitek; (7) Zelnorm; (8) Daptacel; (9) Pediarix; (10) Xyrem; (11) Alinia;  
 (12) Orfadin; (13) Remodulin; (14) Extraneal; Humira  
 CO (1) Lilly; (2) Idec; (3) Astra Zeneca; (5) Amgen; (6) Sanofi Synthelabo;  
 (7) Novartis; (8) Aventis Pasteur; (9) Glaxo SmithKline; (10) Orphan; (11)  
 Romark; (12) Swedish Orphan; (13) United Therapeutics; (14) Baxter

L15 ANSWER 5 OF 8 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED.  
 on STN

ACCESSION NUMBER: 2003080265 EMBASE  
 TITLE: Chronic obstructive pulmonary disease, pollution, pulmonary  
 vascular disease, transplantation, pleural disease, and  
 lung **cancer** in AJRCCM 2002.  
 AUTHOR: Tobin M.J.  
 CORPORATE SOURCE: Dr. M.J. Tobin, Div. of Pulmon./Critical Care Med., Hines  
 Veterans Affairs Hospital, Route 111N, Hines, IL 60141,  
 United States. mtobin2@lumc.edu  
 SOURCE: American Journal of Respiratory and Critical Care Medicine,  
 (1 Feb 2003) 167/3 (356-370).  
 Refs: 98  
 ISSN: 1073-449X CODEN: AJCMED  
 COUNTRY: United States  
 DOCUMENT TYPE: Journal; General Review  
 FILE SEGMENT: 015 Chest Diseases, Thoracic Surgery and Tuberculosis  
 016 Cancer  
 017 Public Health, Social Medicine and Epidemiology  
 037 Drug Literature Index  
 038 Adverse Reactions Titles  
 LANGUAGE: English

CT Medical Descriptors:  
 \*chronic obstructive lung disease: DT, drug therapy  
 \*chronic obstructive lung disease: EP, epidemiology  
 \*chronic obstructive lung disease: ET, etiology  
 \*chronic obstructive lung disease: SU, surgery  
 \*chronic obstructive lung disease: TH, therapy  
 \*lung transplantation  
 \*pulmonary hypertension: DT, drug therapy  
 \*pulmonary hypertension: ET, etiology  
 \*lung embolism: DI, diagnosis  
 \*lung embolism: ET, etiology  
 \*pleura disease: DI, diagnosis

\*pleura disease: ET, etiology  
\*pleura disease: SU, surgery  
\*air pollution  
pathogenesis  
genetic polymorphism  
risk factor  
alpha 1 antitrypsin deficiency: DT, drug therapy  
alpha 1 antitrypsin deficiency: ET, etiology  
mortality  
oxygen therapy  
smoking  
pneumonia: ET, etiology  
pathophysiology  
breathing  
breathing muscle  
cardiovascular disease: SI, side effect  
supraventricular tachycardia: SI, side effect  
drug efficacy  
drug megadose  
corticosteroid therapy  
corticosteroid induced osteoporosis: SI, side effect  
vertebra fracture: SI, side effect  
hip fracture: SI, side effect  
proteinase inhibition  
headache: SI, side effect  
hyperlipidemia: SI, side effect  
myalgia: SI, side effect  
treatment outcome  
asthma: DT, drug therapy  
sickle cell anemia: ET, etiology  
treatment indication  
patient selection  
bronchiolitis: ET, etiology  
    **lung cancer: DI, diagnosis**  
    **lung cancer: EP, epidemiology**  
human  
nonhuman  
clinical trial  
review  
priority journal  
Drug Descriptors:  
technetium 99m  
muscarinic receptor blocking agent: AE, adverse drug reaction  
muscarinic receptor blocking agent: DT, drug therapy  
ipratropium bromide: AE, adverse drug reaction  
ipratropium bromide: DT, drug therapy  
placebo  
theophylline: CT, clinical trial  
theophylline: DO, drug dose  
theophylline: DT, drug therapy  
theophylline: PD, pharmacology  
glucocorticoid: AE, adverse drug reaction  
glucocorticoid: CT, clinical trial  
glucocorticoid: CM, drug comparison  
glucocorticoid: DO, drug dose  
glucocorticoid: DT, drug therapy  
glucocorticoid: IH, inhalational drug administration

glucocorticoid: PO, oral drug administration  
budesonide: AE, adverse drug reaction  
budesonide: CT, clinical trial  
budesonide: DT, drug therapy  
budesonide: IH, inhalational drug administration  
prednisolone: AE, adverse drug reaction  
prednisolone: CT, clinical trial  
prednisolone: DT, drug therapy  
prednisolone: PO, oral drug administration  
fluticasone propionate: CT, clinical trial  
fluticasone propionate: CB, drug combination  
fluticasone propionate: CM, drug comparison  
fluticasone propionate: DO, drug dose  
fluticasone propionate: DT, drug therapy  
fluticasone propionate: IH, inhalational drug administration  
salmeterol: CT, clinical trial  
salmeterol: CB, drug combination  
salmeterol: CM, drug comparison  
salmeterol: DO, drug dose  
salmeterol: DT, drug therapy  
salmeterol: IH, inhalational drug administration  
proteinase inhibitor: AE, adverse drug reaction  
proteinase inhibitor: CT, clinical trial  
proteinase inhibitor: CR, drug concentration  
proteinase inhibitor: DT, drug therapy  
proteinase inhibitor: PD, pharmacology  
proteinase inhibitor: PO, oral drug administration  
retinoic acid: AE, adverse drug reaction  
retinoic acid: CT, clinical trial  
retinoic acid: CR, drug concentration  
retinoic acid: DT, drug therapy  
retinoic acid: PD, pharmacology  
ono 6818: PD, pharmacology  
ono 6818: PO, oral drug administration  
zd 0892: PD, pharmacology  
alpha 1 antitrypsin: DT, drug therapy  
ascorbic acid: DT, drug therapy  
alpha tocopherol: DT, drug therapy  
norfloxacin: PD, pharmacology  
prostacyclin: DT, drug therapy  
nitric oxide: DT, drug therapy  
uniprost: CT, clinical trial  
uniprost: DT, drug therapy  
uniprost: SC, subcutaneous drug administration  
monocrotaline: DT, drug therapy  
monocrotaline: PD, pharmacology  
simvastatin: DT, drug therapy  
simvastatin: PD, pharmacology  
3 hydroxy 3 methylglutaryl coenzyme A: DT, drug therapy  
3 hydroxy 3 methylglutaryl coenzyme A: PD, pharmacology  
sildenafil: DT, drug therapy  
sildenafil: PD, pharmacology  
phosphodiesterase inhibitor: DT, drug therapy  
phosphodiesterase inhibitor: PD, pharmacology  
D dimer: EC, endogenous compound  
cyclosporin: PD, pharmacology  
unclassified drug

RN (technetium 99m) 14133-76-7; (ipratropium bromide) 22254-24-6;  
 (theophylline) 58-55-9, 5967-84-0, 8055-07-0, 8061-56-1, 99007-19-9;  
 (budesonide) 51333-22-3; (prednisolone) 50-24-8; (fluticasone propionate)  
 80474-14-2; (salmeterol) 89365-50-4; (proteinase inhibitor) 37205-61-1;  
 (retinoic acid) 302-79-4; (alpha 1 antitrypsin) 9041-92-3; (ascorbic acid)  
 134-03-2, 15421-15-5, 50-81-7; (alpha tocopherol) 1406-18-4, 1406-70-8,  
 52225-20-4, 58-95-7, 59-02-9; (norfloxacin) 70458-96-7; (prostacyclin)  
 35121-78-9, 61849-14-7; (nitric oxide) 10102-43-9; (uniprost)  
**81846-19-7**; (monocrotaline) 315-22-0, 8051-27-2; (simvastatin)  
 79902-63-9; (3 hydroxy 3 methylglutaryl coenzyme A) 1553-55-5;  
 (sildenafil) 139755-83-2; (cyclosporin) 79217-60-0  
 CN Ono 6818; Zd 0892; Prolastin

L15 ANSWER 6 OF 8 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED.  
 on STN

ACCESSION NUMBER: 2003072829 EMBASE  
 TITLE: Gateways to clinical trials.  
 AUTHOR: Bayes M.; Rabasseda X.; Prous J.R.  
 CORPORATE SOURCE: M. Bayes, Prous Science, P.O. Box 540, 08080 Barcelona,  
 Spain. mbayes@prous.com  
 SOURCE: Methods and Findings in Experimental and Clinical  
 Pharmacology, (2002) 24/10 (703-729). *after 1/10/02*  
 Refs: 180  
 ISSN: 0379-0355 CODEN: MFEPDX  
 COUNTRY: Spain  
 DOCUMENT TYPE: Journal; General Review  
 FILE SEGMENT: 018 Cardiovascular Diseases and Cardiovascular Surgery  
 037 Drug Literature Index  
 038 Adverse Reactions Titles  
 048 Gastroenterology  
 LANGUAGE: English  
 SUMMARY LANGUAGE: English

AB Gateways to Clinical Trials is a guide to the most recent clinical trials  
 in current literature and congresses. The data in the following tables has  
 been retrieved from the Clinical Studies knowledge area of Prous Science  
 Integrity, the drug discovery and development portal,  
<http://integrity.prous.com>. This issue focuses on the following selection  
 of drugs: Abacavir sulfate, adalimumab, AERx morphine sulphate, alefacept,  
 alemtuzumab, alendronic acid sodium salt, alicaforsen sodium, almotriptan,  
 amprenavir, aripiprazole, atenolol, atorvastatin calcium; BSYX-A110;  
 Cantuzumab mertansine, capravirine, CDP-571, CDP-870, celecoxib;  
 Delavirdine mesilate, docetaxel, dofetilide, donepezil hydrochloride,  
 duloxetine hydrochloride, dutasteride, dydrogesterone; Efavirenz,  
 emtricitabine, enjuvia, enteryx, epristeride, erlotinib hydrochloride,  
 escitalopram oxalate, etanercept, etonogestrel, etoricoxib; Fesoterodine,  
 finasteride, flt3ligand; Galantamine hydrobromide, gemtuzumab ozogamicin,  
 genistein, gepirone hydrochloride; Indinavir sulfate, infliximab;  
 Lamivudine, lamivudine/zidovudine/abacavir sulfate, letepirim potassium,  
 levetiracetam, liposomal doxorubicin, lopinavir, lopinavir/ritonavir,  
 losartan potassium; MCC-465, MRA; Nebivolol, nesiritide, nevirapine;  
 Olanzapine, OROS(R)-Methylphenidate hydrochloride; Peginterferon alfa-2a,  
 peginterferon alfa-2b, Pimecrolimus, polyethylene glycol 3350, pramlintide  
 acetate, pregabalin, PRO-2000; Risedronate sodium, risperidone, ritonavir,  
 rituximab, rivastigmine tartrate, rofecoxib, rosuvastatin calcium;  
 Saquinavir mesilate, Stavudine; Tacrolimus, tadalafil, tamsulosin  
 hydrochloride, telmisartan, tomoxetine hydrochloride, treprostinil sodium,  
 trimegestone, trimetrexate; Valdecoxib, venlafaxine hydrochloride;

Zoledronic acid monohydrate. .COPYRG. 2002 Prous Science. All rights reserved.

## CT Medical Descriptors:

\*drug research  
medical literature  
cardiovascular disease: DT, drug therapy  
dose response  
side effect: SI, side effect  
gastrointestinal disease: DT, drug therapy  
diarrhea: SI, side effect  
virus infection: DT, drug therapy  
metabolic disorder: DT, drug therapy  
nutritional disorder: DT, drug therapy  
musculoskeletal disease: DT, drug therapy  
connective tissue disease  
bone disease: DT, drug therapy  
**neoplasm: DT, drug therapy**  
neurologic disease: DT, drug therapy  
mental disease: DT, drug therapy  
kidney disease: DT, drug therapy  
genital system disease: DT, drug therapy  
thrombophlebitis: SI, side effect  
breast disease: DT, drug therapy  
skin disease: DT, drug therapy  
human  
clinical trial  
meta analysis  
review

## Drug Descriptors:

nesiritide: CT, clinical trial  
nesiritide: CB, drug combination  
nesiritide: CM, drug comparison  
nesiritide: DT, drug therapy  
nesiritide: IV, intravenous drug administration  
glyceryl trinitrate: CT, clinical trial  
glyceryl trinitrate: CM, drug comparison  
glyceryl trinitrate: DT, drug therapy  
glyceryl trinitrate: IV, intravenous drug administration  
milrinone: CT, clinical trial  
milrinone: CB, drug combination  
milrinone: DT, drug therapy  
dofetilide: CT, clinical trial  
dofetilide: DT, drug therapy  
losartan: CT, clinical trial  
losartan: DT, drug therapy  
atenolol: CT, clinical trial  
atenolol: DT, drug therapy  
ascorbic acid: CT, clinical trial  
ascorbic acid: CM, drug comparison  
ascorbic acid: DT, drug therapy  
ascorbic acid: PO, oral drug administration  
atorvastatin: CT, clinical trial  
atorvastatin: CM, drug comparison  
atorvastatin: DT, drug therapy  
atorvastatin: PO, oral drug administration  
enalapril: CT, clinical trial  
enalapril: CM, drug comparison

enalapril: DT, drug therapy  
telmisartan: CT, clinical trial  
telmisartan: CM, drug comparison  
telmisartan: DT, drug therapy  
nebivolol: CT, clinical trial  
nebivolol: DT, drug therapy  
uniprost: CT, clinical trial  
uniprost: DO, drug dose  
uniprost: DT, drug therapy  
rosuvastatin: AE, adverse drug reaction  
rosuvastatin: CT, clinical trial  
rosuvastatin: DT, drug therapy  
macrogol: AE, adverse drug reaction  
macrogol: CT, clinical trial  
macrogol: DO, drug dose  
macrogol: DT, drug therapy  
alicaforsen: CT, clinical trial  
alicaforsen: DT, drug therapy  
alicaforsen: IV, intravenous drug administration  
    **tumor necrosis factor alpha antibody: AE, adverse drug reaction**  
    **tumor necrosis factor alpha antibody: CT, clinical trial**  
    **tumor necrosis factor alpha antibody: DT, drug therapy**  
    **tumor necrosis factor alpha antibody: IV, intravenous drug**  
**administration**  
etoricoxib: CT, clinical trial  
etoricoxib: CM, drug comparison  
etoricoxib: DT, drug therapy  
etoricoxib: PO, oral drug administration  
rofecoxib: CT, clinical trial  
rofecoxib: CM, drug comparison  
rofecoxib: DT, drug therapy  
diclofenac: CT, clinical trial  
diclofenac: CM, drug comparison  
diclofenac: DT, drug therapy  
infliximab: CT, clinical trial  
infliximab: CB, drug combination  
infliximab: DT, drug therapy  
infliximab: IV, intravenous drug administration  
prednisone: CT, clinical trial  
prednisone: CB, drug combination  
prednisone: DT, drug therapy  
peginterferon alpha2a: CT, clinical trial  
peginterferon alpha2a: CB, drug combination  
peginterferon alpha2a: DT, drug therapy  
peginterferon alpha2a: SC, subcutaneous drug administration  
ribavirin: CT, clinical trial  
ribavirin: CB, drug combination  
ribavirin: IT, drug interaction  
peginterferon alpha2b: CT, clinical trial  
peginterferon alpha2b: CB, drug combination  
peginterferon alpha2b: DT, drug therapy  
lamivudine: CT, clinical trial  
lamivudine: CB, drug combination  
lamivudine: DT, drug therapy  
lamivudine: PO, oral drug administration  
abacavir: CT, clinical trial  
abacavir: CB, drug combination

abacavir: DT, drug therapy  
 zidovudine: CT, clinical trial  
 zidovudine: CB, drug combination  
 zidovudine: DT, drug therapy  
 stavudine: CT, clinical trial  
 stavudine: CB, drug combination  
 stavudine: DT, drug therapy  
 delavirdine: CT, clinical trial  
 delavirdine: CB, drug combination  
 delavirdine: DT, drug therapy  
 unindexed drug  
 RN (nesiritide) 124584-08-3, 189032-40-4; (glyceryl trinitrate) 55-63-0;  
 (milrinone) 78415-72-2; (dofetilide) 115256-11-6; (losartan) 114798-26-4;  
 (atenolol) 29122-68-7; (ascorbic acid) 134-03-2, 15421-15-5, 50-81-7;  
 (atorvastatin) 134523-00-5, 134523-03-8; (enalapril) 75847-73-3;  
 (telmisartan) 144701-48-4; (nebivolol) 99200-09-6; (uniprost)  
**81846-19-7**; (rosuvastatin) 147098-18-8, 147098-20-2; (macrogol)  
 25322-68-3; (alicaforfen) 142442-63-5, 185229-68-9, 331257-52-4;  
 (etoricoxib) 202409-33-4, 202409-40-3; (rofecoxib) 162011-90-7,  
 186912-82-3; (diclofenac) 15307-79-6, 15307-86-5; (infliximab)  
 170277-31-3; (prednisone) 53-03-2; (peginterferon alpha2a) 198153-51-4;  
 (ribavirin) 36791-04-5; (peginterferon alpha2b) 215647-85-1; (lamivudine)  
 134678-17-4, 134680-32-3; (abacavir) 136470-78-5, 188062-50-2;  
 (zidovudine) 30516-87-1; (stavudine) 3056-17-5; (delavirdine) 136817-59-9  
 CN Cdp 571

L15 ANSWER 7 OF 8 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED.  
 on STN

ACCESSION NUMBER: 2002412976 EMBASE  
 TITLE: News focus.  
 SOURCE: Current Drug Discovery, (1 Nov 2002) -/NOV. (11).  
 ISSN: 1472-7463 CODEN: CDDUAI  
 COUNTRY: United Kingdom  
 DOCUMENT TYPE: Journal; Note  
 FILE SEGMENT: 003 Endocrinology  
 004 Microbiology  
 016 Cancer  
 018 Cardiovascular Diseases and Cardiovascular Surgery  
 030 Pharmacology  
 037 Drug Literature Index  
 LANGUAGE: English

CT Medical Descriptors:  
 non insulin dependent diabetes mellitus: DT, drug therapy  
 glucose blood level  
 premature labor: DT, drug therapy  
 ovary insufficiency  
 fertilization in vitro  
 growth hormone deficiency: DT, drug therapy  
**solid tumor: DT, drug therapy**  
**antineoplastic activity**  
 aspergillosis: DT, drug therapy  
 bacterial infection: DT, drug therapy  
 drug potency  
 drug structure  
 antibacterial activity  
 pulmonary hypertension: DT, drug therapy  
 human

controlled study

note

Drug Descriptors:

\*protein tyrosine phosphatase inhibitor: DT, drug therapy

\*protein tyrosine phosphatase inhibitor: PD, pharmacology

\*protein tyrosine phosphatase inhibitor: PO, oral drug administration

**\*antineoplastic agent: DT, drug therapy**

**\*antineoplastic agent: PD, pharmacology**

\*antiinfective agent: AN, drug analysis

\*antiinfective agent: CM, drug comparison

\*antiinfective agent: DT, drug therapy

\*antiinfective agent: PD, pharmacology

\*antiinfective agent: IV, intravenous drug administration

as 602305: DT, drug therapy

as 602305: PO, oral drug administration

oxytocin antagonist: DT, drug therapy

oxytocin antagonist: PO, oral drug administration

recombinant follitropin: PD, pharmacology

sermorelin: DT, drug therapy

abt 100: DT, drug therapy

abt 100: PD, pharmacology

abt 839

protein farnesyltransferase inhibitor: DT, drug therapy

protein farnesyltransferase inhibitor: PD, pharmacology

abt 567: PD, pharmacology

angiogenesis inhibitor: PD, pharmacology

n [[5 [(2 amino 3 mercaptopropyl)amino][1,1' biphenyl] 2  
yl]carbonyl]methionine

bms 379224: DT, drug therapy

bms 379224: IV, intravenous drug administration

antifungal agent: DT, drug therapy

antifungal agent: IV, intravenous drug administration

ravuconazole

chorismate synthase inhibitor: DT, drug therapy

chorismate synthase inhibitor: PD, pharmacology

phosphopantethiene adenyltransferase inhibitor: DT, drug therapy

phosphopantethiene adenyltransferase inhibitor: PD, pharmacology

ptx 110130: CM, drug comparison

ptx 110130: PD, pharmacology

ptx 008313: AN, drug analysis

ptx 008313: CM, drug comparison

ptx 008313: PD, pharmacology

a 00000764: AN, drug analysis

a 00000764: PD, pharmacology

a 00026158: PD, pharmacology

a 00000762: PD, pharmacology

ar 328: PD, pharmacology

antibiotic agent: AN, drug analysis

antibiotic agent: CM, drug comparison

antibiotic agent: DT, drug therapy

antibiotic agent: PD, pharmacology

uniprost: DT, drug therapy

uniprost: SC, subcutaneous drug administration

gepirone: PD, pharmacology

mirtazapine

antidepressant agent: PD, pharmacology

unindexed drug

unclassified drug  
RN (sermorelin) 86168-78-7; (n [[5 [(2 amino 3 mercaptopropyl)amino][1,1'  
biphenyl] 2 yl]carbonyl]methionine) 170006-72-1; (ravuconazole)  
182760-06-1; (uniprost) **81846-19-7**; (gepirone) 83928-66-9,  
83928-76-1; (mirtazapine) 61337-67-5  
CN (1) As 602305; (2) Abt 100; (3) Abt 567; (4) Abt 839; (5) Fti 276; (6) Bms  
379224; (7) Ptx 110130; (8) Ptx 008313; (9) A 00000764; (10) A 00000762;  
(11) A 00026158; (12) Ar 328; (13) Ariza; (14) Remeron  
CO (1) Serono; (4) Abbott; (5) University of Pittsburgh; (6) Bristol Myers  
Squibb; (8) PanTherix; (11) Arrow; (12) Arpida; (14) Organon

L15 ANSWER 8 OF 8 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED.  
on STN

ACCESSION NUMBER: 2002123171 EMBASE

TITLE: News focus.

SOURCE: Current Drug Discovery, (2002) -/MAR. (15-18).

ISSN: 1472-7463 CODEN: CDDUAI

COUNTRY: United Kingdom

DOCUMENT TYPE: Journal; Article

FILE SEGMENT: 016 Cancer  
017 Public Health, Social Medicine and Epidemiology  
030 Pharmacology  
037 Drug Literature Index  
039 Pharmacy

LANGUAGE: English

CT Medical Descriptors:  
multidrug resistance  
degenerative disease: DT, drug therapy  
diabetes mellitus: DT, drug therapy  
graft versus host reaction: DT, drug therapy  
bacterial infection: DT, drug therapy  
Human immunodeficiency virus infection: DT, drug therapy  
**basal cell carcinoma: DT, drug therapy**  
actinic keratosis: DT, drug therapy  
pulmonary hypertension: DT, drug therapy  
melanoma: DT, drug therapy  
cystic fibrosis: DT, drug therapy  
**colorectal cancer: DT, drug therapy**  
heart failure: DT, drug therapy  
obesity: DT, drug therapy  
erectile dysfunction: DT, drug therapy  
female sexual dysfunction: DT, drug therapy  
hip fracture: DT, drug therapy  
human  
nonhuman  
clinical trial  
controlled study  
article  
Drug Descriptors:  
\*new drug: CT, clinical trial  
\*new drug: AN, drug analysis  
\*new drug: DT, drug therapy  
\*new drug: PR, pharmaceuticals  
\*new drug: PD, pharmacology  
\*new drug: NA, intranasal drug administration  
\*new drug: PO, oral drug administration  
protein inhibitor: CT, clinical trial

protein inhibitor: DT, drug therapy  
 ont 093: CT, clinical trial  
 ont 093: DT, drug therapy  
 glutamate receptor antagonist: DV, drug development  
 glutamate receptor antagonist: DT, drug therapy  
 ro 68 0921: DV, drug development  
 ro 68 0921: DT, drug therapy  
 ro 64 5229: DV, drug development  
 ro 64 5229: DT, drug therapy  
 metalloproteinase inhibitor: DV, drug development  
 metalloproteinase inhibitor: DT, drug therapy  
 kb r7785: DV, drug development  
 kb r7785: DT, drug therapy  
 antiinfective agent: AN, drug analysis  
 antiinfective agent: DV, drug development  
 antiinfective agent: PD, pharmacology  
 pyrrole derivative: AN, drug analysis  
 pyrrole derivative: DV, drug development  
 pyrrole derivative: PD, pharmacology  
 tenofovir disoproxil: DT, drug therapy  
     **antineoplastic agent: DT, drug therapy**  
     **antineoplastic agent: PR, pharmaceuticals**  
 metvix pdt: DT, drug therapy  
 metvix pdt: PR, pharmaceuticals  
 uniprost: CT, clinical trial  
 uniprost: DT, drug therapy  
 doxycycline: PO, oral drug administration  
 bacterial vaccine: DT, drug therapy  
 aerugen: DT, drug therapy  
     **cancer vaccine: CT, clinical trial**  
     **cancer vaccine: DT, drug therapy**  
 oncopophage: DT, drug therapy  
 theratope: CT, clinical trial  
 theratope: DT, drug therapy  
 angiogenesis inhibitor: CT, clinical trial  
 angiogenesis inhibitor: DT, drug therapy  
 semaxinib: CT, clinical trial  
 semaxinib: DT, drug therapy  
 endothelin receptor antagonist: CT, clinical trial  
 endothelin receptor antagonist: DT, drug therapy  
 bosentan: CT, clinical trial  
 bosentan: DT, drug therapy  
 antiobesity agent: CT, clinical trial  
 antiobesity agent: DT, drug therapy  
 aod 9604: CT, clinical trial  
 aod 9604: DT, drug therapy  
 apomorphine: DT, drug therapy  
 apomorphine: NA, intranasal drug administration  
 growth hormone releasing factor: DT, drug therapy  
 th 9507: DT, drug therapy  
 unindexed drug  
 unclassified drug  
 pennsaid  
 viread

RN (tenofovir disoproxil) 202138-50-9; (uniprost) **81846-19-7**;  
 (doxycycline) 10592-13-9, 17086-28-1, 564-25-0; (apomorphine) 314-19-2,  
 58-00-4; (growth hormone releasing factor) 83930-13-6, 9034-39-3

CN (1) Ont 093; (2) Ro 68 0921; (3) Ro 64 5229; (4) Kb r7785; (5) Metvix pdt;  
(6) Remodulin; (7) Oncophage; (8) Periostat; (9) Pennsaid; (10) Aerugen;  
(11) Theratope; (12) Semaxinib; (13) Tracleer; Viread  
CO (1) Ontogen; (3) Hoffmann La Roche; (4) Organon; (5) PhotoCure; (6) United  
Therapeutics; (7) Antigenics; (8) Collagenex; (9) Dimethaid; (10) Berna;  
(11) Biomira; (12) Pharmacia; (13) Genentech; Genelabs; Natestch